Ajai Chari, MD

Panelists discuss how the follow-up results from the RedirecTT-1 study provide insights into the long-term efficacy and safety of bispecific antibody combinations in treating relapsed/refractory multiple myeloma, potentially shaping future treatment approaches for this challenging disease.

Panelists discuss how patient-specific factors like age, comorbidities, cytogenetic risk status, and personal preferences guide decisions to deviate from standard protocols, with particular attention to frailty scores and organ function when considering treatment intensity.

Panelists discuss how the TRIMM-2 study explores the potential of combining bispecific antibodies to enhance treatment efficacy in patients with relapsed/refractory multiple myeloma, potentially offering a novel therapeutic strategy for this difficult-to-treat condition.

Panelists discuss how Talquetamab, a novel GPRC5DxCD3 bispecific antibody, shows promising results in treating relapsed/refractory multiple myeloma based on the MonumenTAL-1 trial data, potentially offering a new therapeutic option for this challenging patient population.

Panelists discuss how VRd (bortezomib, lenalidomide, dexamethasone) remains the standard frontline regimen for transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, though some now consider adding daratumumab (dara-VRd) in high-risk cases.

Noopur Raje, MD, discusses the role of T-cell affinity in bispecific therapy for patients with relapsed/refractory multiple myeloma and how it impacts treatment practices.

The panel discusses the benefits of having multiple BCMA-targeting bispecifics available for patients with relapsed/refractory multiple myeloma.

Rafael Fonseca, MD, discusses the role of bispecifics in relapsed/refractory multiple myeloma and the implications of incorporating them into combination regimens.

Noopur Raje, MD, reviews clinical research on elranatamab combination therapy in patients with relapsed/refractory multiple myeloma.

Focusing on clinical trials evaluating combination strategies with bispecifics, Larysa J. Sanchez, MD, discusses the TRIMM-2, TRIMM-3, and MajesTEC-3 studies.

Rafael Fonseca, MD, discusses the MonumenTAL-2 and MonumenTAL-3 clinical trials investigating talquetamab combination strategies in relapsed/refractory multiple myeloma.

Hematologist-oncologists discuss GPRC5D-targeting treatments that are currently in development for patients with relapsed/refractory multiple myeloma.

Noopur Raje, MD, shares clinical perspectives on her experience treating patients with prior BCMA bispecific exposure and provides insights on adverse event management practices in patients receiving talquetamab.

Larysa J. Sanchez, MD, discusses recent efficacy data presented at EHA 2024 from the long-term follow-up results of the phase 1/2 MonumenTAL-1 study investigating talquetamab in relapsed/refractory multiple myeloma.

A panel of experts on multiple myeloma discuss the importance of GPRC5D as a target of interest in relapsed/refractory disease and discuss their experiences with talquetamab in clinical practice.

The expert panel closes the discussion with key takeaways on the relapsed/refractory multiple myeloma treatment landscape.

Multiple myeloma–treating oncologists provide comprehensive insights on deciding between bispecific antibody monotherapy, combination therapy, and CAR T-cell therapy.

The panel continues their discussion on adverse effect management with a focus on GPRC5D-targeting bispecific antibodies in multiple myeloma.

Multiple myeloma specialists discuss the management of toxicities from BCMA-targeting bispecific antibodies.

Comprehensive insights on the management of adverse effects from bispecific antibodies in the treatment of multiple myeloma.

Expert oncologists discuss dosing considerations for bispecific antibodies in the treatment of patients with multiple myeloma.

A review of clinical trial data on bispecific antibodies in multiple myeloma and clinical insights on how these medications have changed clinical practice.

The panel reviews the profiles of 2 patients with multiple myeloma and provides their initial thoughts regarding treatment approaches.

Expert perspectives on treatment decision-making in early-relapse multiple myeloma and the efficacy of CAR T-cell therapy.

A panel of oncologists give an overview of clinical trial data surrounding the management of early-relapse multiple myeloma.

In the context of other clinical trials for patients with relapsed/refractory multiple myeloma, Ajai Chari, MD, and Carolina Schinke, MD, review data from TRiMM-2.

Expert perspectives on the real-world use of combination teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.

Centering discussion on RedirecTT-1, expert hematologist-oncologists consider safety and efficacy data with the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.

Shared perspective on available novel therapies in relapsed/refractory multiple myeloma and how best to sequence these agents.

Expert hematologist-oncologists identify long-term data from MonumenTAL-1 regarding infection rates in patients with relapsed/refractory multiple myeloma.